Article Text

Download PDFPDF

Original article
Comparison of early warning scores in patients with COPD exacerbation: DECAF and NEWS score
  1. Carlos Echevarria1,2,
  2. John Steer1,3,
  3. Stephen C Bourke1,3
  1. 1 Newcastle University, Newcastle upon Tyne, UK
  2. 2 Respiratory Medicine, Royal Victoria Infimrary, Newcastle upon Tyne, UK
  3. 3 Respiratory Medicine, North Tyneside General Hospital, North Shields, UK
  1. Correspondence to Prof Stephen C Bourke, Respiratory Medicine, North Tyneside General Hospital, North Shields NE29 8NH, UK; stephen.bourke{at}nhct.nhs.uk

Footnotes

  • Contributors The study was conceived by SCB and designed by CE, JS and SCB. CE performed the statistical analyses. All authors contributed to data analysis and interpretation, and all were involved in drafting the manuscript and approving the final version. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

  • Funding Department of Health, Breathe North appeal, Northumbria NHS Foundation Trust Teaching and Research Fellowship programme and Novartis Pharmaceuticals UK.

  • Disclaimer The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.

  • Competing interests All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: JS has no conflicts of interest to declare. CE reports grants from National Institute of Health Research, outside of the submitted work. SCB reports grants from National Institute of Health Research, Philips Respironics and from Pfizer Open Air, personal fees from Pfizer, AstraZeneca and ResMed, and non-financial support from Boehringer Ingelheim and GlaxoSmithKline outside the submitted work. No author has financial relationships with any organisation that might have an interest in the submitted work.

  • Patient consent for publication Not required.

  • Ethics approval The study was approved by NRES Committee North East, UK (REC reference: 12/NE/0379).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available on reasonable request.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Contributors The study was conceived by SCB and designed by CE, JS and SCB. CE performed the statistical analyses. All authors contributed to data analysis and interpretation, and all were involved in drafting the manuscript and approving the final version. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

  • Funding Department of Health, Breathe North appeal, Northumbria NHS Foundation Trust Teaching and Research Fellowship programme and Novartis Pharmaceuticals UK.

  • Disclaimer The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report.

  • Competing interests All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: JS has no conflicts of interest to declare. CE reports grants from National Institute of Health Research, outside of the submitted work. SCB reports grants from National Institute of Health Research, Philips Respironics and from Pfizer Open Air, personal fees from Pfizer, AstraZeneca and ResMed, and non-financial support from Boehringer Ingelheim and GlaxoSmithKline outside the submitted work. No author has financial relationships with any organisation that might have an interest in the submitted work.

  • Patient consent for publication Not required.

  • Ethics approval The study was approved by NRES Committee North East, UK (REC reference: 12/NE/0379).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement Data are available on reasonable request.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Editorial
    Eui-Sik Suh Beth Sage